2023年2月2日,

组织老人安德森博士加入倒带´s董事会倒带疗法,一个公司开发first-in-class demyelination-associated疾病的治疗,今天宣布了额外的资金,以日长石生命科学企业/ s加入的新投资者,参与现有投资者勃林格殷格翰集团风险基金,m .企业PMV,吉玛Frisius昏聩,和CD3 / KU鲁汶。老人安德森博士,普通合伙人日长石生命科学企业/ S,将加入倒带疗法´董事会。交易的财务细节没有透露。所得将用于提前退疗法´导致程序进入临床开发和进一步扩大药物候选人的公司´s管道设计恢复remyelination中枢神经系统(CNS)的函数。髓鞘形成保护层在神经元和对他们的正常运行至关重要。神经退行性疾病如多发性硬化症与损坏,髓鞘恶化,最终导致一系列症状,如抑郁、焦虑、易怒、甚至死亡由于分解的重要神经功能。“我们很高兴欢迎日长石生命科学企业作为一种新的投资者与我们现有的投资者财团的继续支持,”安雅Harmeier说,首席执行官在倒带疗法。“额外融资不仅加强了我们的顶级投资者基础,但也允许我们加速我们的发展导致程序进入临床的发展。此外,我们期待着与老人Andersson作为我们的董事会新成员。”“停止甚至恢复髓鞘脱失是一项非常具有挑战性的任务。生成的数据回放治疗到目前为止支持一个真正的小说的作用机制,并将允许该公司启动关键中枢神经系统临床试验适应症,”老人安德森说,日长石生命科学博士学位,一般合伙人企业/ S。 “Moreover, Rewind has a strong patent estate and a team with long research and development expertise in the field of remyelination therapeutics. The combination of this extensive industry expertise and the high unmet medical need in neurogenerative disorders has convinced us to join forces with Rewind´s existing, internationally renowned investor syndicate.” Demyelinating diseases such as multiple sclerosis affect millions of patients worldwide. Rewind´s approach is based on ensuring proper functioning of myelinating oligodendrocytes and oligodendrocyte precursor cells (OPCs), both of which are drivers of the myelination process. The Company´s goal is to establish a novel therapeutic principle that is universally applicable to all demyelination diseases. This provides significant therapeutic potential for treating a broad range of demyelination-inducing conditions. ### About Rewind Therapeutics Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis or nerve injuries. A common feature of these illnesses is the loss of the myelin sheath, a protective cover wrapped around the nerves. Repairing or re-installing this sheath (i.e., remyelination) is a crucial factor for halting or reversing disease progression or even curing these diseases. Rewind´s team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. Based in Leuven, Belgium, Rewind is backed by top-tier life science investors such as Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Sunstone Life Science Ventures, Gemma Frisius Fonds, and CD3/ KU Leuven. About Sunstone Life Science Ventures Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Managing total funds of €500 million, Sunstone Life Science Ventures focuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 50 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. For more information, please visit: https://sunstone.eu/ For further information please contact: Rewind Therapeutics